129
Participants
Start Date
August 9, 2022
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2026
anitocabtagene-autoleucel
Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
Levine Cancer Institute, Charlotte
Northside Hospital, Atlanta
Moffitt Cancer Center, Tampa
Karmanos Cancer Institute, Detroit
Froedtert Hospital & the Medical College of Wisconsin, Milwaukee
University of Wisconsin Clinical Science Center, Madison
University of Chicago Medical Center, Chicago
University of Arkansas for Medical Sciences, Little Rock
University of Texas Southwestern Medical Center, Dallas
The University of Texas MD Anderson Cancer Center, Houston
Colorado Blood Cancer Institute, Denver
Huntsman Cancer Institute, University of Utah, Salt Lake City
HonorHealth Cancer Transplant Institute, Scottsdale
Oregon Health & Science University (OHSU), Portland
Massachusetts General Hospital, Boston
Dana-Farber Cancer Institute, Boston
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Collaborators (1)
Arcellx, Inc.
INDUSTRY
Kite, A Gilead Company
INDUSTRY